GlassScriptPhysician profile
Jamaluddin Moloo
NPI 1235101197
$272,485.26
in general payments reported to CMS, 2019-2025
12 companies · $89K in 2025
The $89K reported for 2025 was more than what 98% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2021: $416 · 2022: $86K · 2023: $35K · 2024: $62K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $137K · Consulting Fee: $33K · Travel and Lodging: $11K · Food and Beverage: $4,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,262.11 |
| Consulting Fee | $33,038.76 |
| Travel and Lodging | $11,008.88 |
| Food and Beverage | $4,317.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $271,820.17 | 2019-2025 | Ffrct |
| Cleerly, INC. | $181.23 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Novo Nordisk INC | $112.02 | 2025 | Wegovy |
| Amgen INC. | $102.02 | 2023-2025 | Evenity, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $61.87 | 2025 | |
| Novartis Pharmaceuticals Corporation | $56.65 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $36.62 | 2025 | Wainua, Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $30.34 | 2023 | Arcalyst |
| Lilly USA, LLC | $23.47 | 2025 | Zepbound |
| Actelion Pharmaceuticals US, INC. | $22.47 | 2025 | Uptravi, Opsumit |
| Pfizer INC. | $22.25 | 2024 | |
| Esperion Therapeutics, INC. | $16.15 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamaluddin Moloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.